Diagnosing sarcoma can be particularly challenging due to the rarity and diversity of these cancers. The process often requires specialist imaging, pathology expertise, and multidisciplinary input. Where concerns arise about delays in diagnosis, it may also be necessary to consider whether the care provided met an appropriate standard.
As Sarcoma Awareness Month highlights the importance of recognising the signs and symptoms of these rare cancers, it also provides an opportunity to consider the challenges associated with diagnosis and the potentially significant consequences of diagnostic delay.
This is the second article in our two-part sarcoma series. If you have not already done so, you may wish to read part one, which explores sarcoma awareness, common subtypes, and how these cancers typically present.
Diagnosing Sarcoma
Diagnosis begins with clinical examination and imaging. MRI represents the gold standard for soft tissue characterisation, and core needle biopsy under image guidance provides tissue for diagnosis whilst minimising complications. Biopsy planning is critical and procedures should involve specialist centres providing ongoing treatment.
Pathological diagnosis challenges even experienced pathologists due to the rarity and diversity of sarcoma. Accurate sub-typing requires specialised expertise, immunohistochemistry, molecular testing, and expert consultation. Misdiagnosis can lead to inappropriate treatment, and national guidelines recommend specialist pathologist review before treatment.
Staging investigations determine the extent of disease and whether the cancer has spread beyond the local tumour. Accurate staging ensures clinicians are able to assess the most appropriate therapy and treatment for each individual’s circumstances.
Treating sarcoma: the importance of multidisciplinary care
Surgery remains the cornerstone for localised sarcomas, with the aim of achieving complete excision with adequate margins. Limb-sparing surgery is standard for extremity sarcomas, however in some situations amputation or other significantly extensive surgery may be required.
Radiotherapy reduces the risk of local recurrence and may be delivered before or after surgery depending on the tumour characteristics. Modern techniques such as proton beam radiotherapy enable precise targeting whilst minimising the amount of normal tissue which is exposed to the radiation.
The impact and efficacy of chemotherapy varies across sarcoma subtypes. For high-grade soft tissue sarcomas, perioperative chemotherapy remains controversial, whilst Ewing sarcoma and osteosarcoma have been shown to have strong to intensive chemotherapy protocols. Where the disease is advanced, palliative chemotherapy may provide symptom control and slow the spread of disease, in some cases achieving remission.
Targeted therapies and immunotherapies offer hope for advanced disease, in some situations showing significant benefit, and research into these approaches is ongoing.
Delayed diagnosis claims: Understanding your legal rights and options
For a medical negligence claim to succeed, a claimant needs to be able to demonstrate that the care or treatment provided fell below a reasonable standard, and that they have suffered injury or damage as a result of this negligent care.
In delayed diagnosis cases, claimants must be able to prove that, on the balance of probability, earlier diagnosis would have led to different treatment options or improved the outcome. Generally speaking, the longer a delay, the more substantial the impact. Independent specialist medical expert opinion is however required in each case to carefully assess the standard of care provided and the impact of any substandard care.
Damages reflect harm from negligent care: pain, suffering, loss of amenity, and financial losses including earnings and care costs. Negligent delays causing extensive surgery warrant compensation for additional disability and scarring. Progression from curable to incurable disease requires damages for lost life years and terminal illness suffering.
The importance of specialist legal representation
Medical negligence claims are complex, and those relating to sarcoma require specialist knowledge and experience to ensure all aspects of the care provided are investigated and the full impact of any substandard care is recognised. At Tees, we have a specialist team who deal with cases involving sarcoma and have significant experience in successfully supporting claimants and their families through the litigation process.
The majority of these cases are funded by (“no win, no fee”) conditional fee agreements that allow claimants to investigate and pursue legal claims at no financial risk. Medical negligence claims often take years to resolve, and our specialist medical negligence team are here to listen, understand your concerns, and guide you every step of the way.
Moving forward: support and resources
Specialist sarcoma charities such as Sarcoma UK and the Bone Cancer Research Trust provide vital information, emotional support, financial support, and practical assistance through helplines, online communities, and educational resources whilst funding research and advocating for improved services. Some offer rehabilitation services, occupational therapy, and assistance with access to appropriate aids and equipment.
Peer support through formal groups or informal connections offers unique benefits. Connecting with others who have faced similar challenges reduces isolation and provides hope, practical advice, and validation. Specialist sarcoma charities facilitate connection with others facing similar challenges, providing hope and practical advice.
Conclusion
Sarcoma cases are often complex, requiring specialist investigation, treatment planning, and expert pathological assessment. Where diagnosis is delayed, the consequences for patients can be significant, affecting both treatment options and long-term outcomes. In some cases, it may be appropriate to investigate whether negligent care contributed to that delay and whether compensation may be available.
For a broader understanding of sarcoma, including its various subtypes, typical presentations, and the importance of early recognition, readers can refer to Part One of this series, which explores why greater awareness remains crucial to improving patient outcomes.
